Additionally, our study also provided suggestive evidence for the potential therapeutic use of ANGPTL3 inhibitors for both hypothyroidism and hyperthyroidism, while showing that LPL activation was related to increasing hyperthyroidism risk. The gene discussed is LPL; the disease is hypothyroidism.